Loading organizations...
F-Star Therapeutics is a clinical-stage biopharmaceutical company developing novel immuno-oncology therapies. The company engineers tetravalent bispecific antibodies designed to engage multiple targets concurrently within the tumor microenvironment. This approach aims to enhance the body's immune response, offering a distinct mechanism to combat various forms of cancer.
Established in 2002, the company counts Florian Ruker among its co-founders. The foundational insight driving F-Star was the potential of advanced antibody engineering to overcome limitations inherent in traditional monoclonal antibodies. This expertise sought to unlock greater therapeutic efficacy, particularly within the complex biology of cancer and immune system interaction.
F-Star Therapeutics focuses on delivering innovative treatment options for cancer patients. Its long-term vision is to transform cancer care through its proprietary bispecific antibody platform, advancing multiple programs towards clinical success. The company aims to significantly improve patient outcomes by establishing new standards.
F-Star Therapeutics has raised $74.7M across 6 funding rounds.
F-Star Therapeutics has raised $74.7M in total across 6 funding rounds.
F-star Therapeutics is a clinical‑stage immuno‑oncology company that develops engineered tetravalent bispecific antibodies (its “mAb2” platform) to improve immune checkpoint targeting for cancer treatment; it is based in Cambridge, UK and Cambridge, MA and has partnered with multiple large biopharma firms while advancing several clinical programs including FS‑118 (LAG‑3 × PD‑L1).[1][2]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biopharma Landscape
Quick Take & Future Outlook
If you’d like, I can extract the current pipeline table (program names, targets, and clinical phase) and list the company’s publicly disclosed partners and recent clinical milestones with source citations.
F-Star Therapeutics has raised $74.7M in total across 6 funding rounds.
F-Star Therapeutics's investors include Atlas Venture, INKEF Capital, Aescap Venture, MP Healthcare Venture Management, MS Ventures, SR One, TVM Capital, Deborah Harland, M Ventures, Novo Ventures, Axel Polack.
F-Star Therapeutics has raised $74.7M across 6 funding rounds. Most recently, it raised $9.0M Series A in October 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2013 | $9.0M Series A | Atlas Venture, INKEF Capital, Aescap Venture, MP Healthcare Venture Management, MS Ventures, SR One, TVM Capital | |
| Apr 13, 2011 | $21.7M Other Equity | Deborah Harland | Aescap Venture, Atlas Venture, MP Healthcare Venture Management, M Ventures, Novo Ventures, Axel Polack |
| Apr 1, 2011 | $22.0M Venture Round | Atlas Venture, INKEF Capital | |
| Jan 1, 2010 | $12.0M Series A | MP Healthcare Venture Management, M Ventures | Atlas Venture, INKEF Capital, Aescap Venture, Novo Ventures, TVM Capital |
| Sep 1, 2007 | $8.0M Series A | Atlas Venture | |
| Jan 1, 2007 | $2.0M Seed | Atlas Venture |